Argonaut Announces Collaboration with Pfizer Inc.Business Editors/Health & Medical Writers FOSTER CITY, Calif.--(BW HealthWire)--Oct. 30, 2001 Argonaut Technologies, Inc. (Nasdaq:AGNT AGNT Association for Global New Thought AGNT Agent Table ) today announced that it has entered into a multi-year collaborative research agreement with Pfizer Inc. where Argonaut will assess and develop new technologies and instrument systems relevant to Pfizer Global Research & Development programs. Under the terms of the agreement, Pfizer will fund Argonaut's assessment and development efforts related to the new tools. Argonaut will have exclusive rights to commercialize technologies developed within the collaboration. "We are excited about partnering with Pfizer to develop innovative and strategic systems that improve and expand the productivity of chemists This is a list of famous chemists: (alphabetical order) : Top - 0–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z A
n. 1. High respect, as that shown for special merit; esteem: the honor shown to a Nobel laureate. 2. a. Good name; reputation. b. to work with their scientists to help speed research and development of new medicines." "The collaboration with Pfizer allows us to extend our tradition of developing customer driven solutions and expand our technology platforms for chemistry development," stated Jan Hughes, chief technical officer of Argonaut. "Working with Pfizer will provide Argonaut with additional resources to fully assess new technologies that provide cost-effective and simplified methodologies." Financial terms of the collaboration were not disclosed and involve several payments during the term of the agreement. Argonaut will be hosting a conference call at 2:00 p.m. Pacific/ 5:00 p.m. Eastern, today, October 30, 2001, to discuss this agreement and Argonaut's financial results for the third quarter ended September 30, 2001. Interested parties may listen to the conference call via live audio broadcast over the Internet available at www.argotech.com. For those unable to participate on the live call, a 24-hour replay will be available for seven days after the call at www.argotech.com or by calling 888-843-8996 and giving the following passcode: 4767928. Argonaut Technologies Argonaut Technologies, Inc. is a pioneer in the development of innovative products that speed and simplify how chemists discover and test new chemical entities. Our products enable chemists to increase their productivity, reduce their operating costs operating costs npl → gastos mpl operacionales through automation and process simplification, achieve faster time-to-market for new products, and cost-effectively explore the increasing number of drug targets available for drug development. We provide solutions that are used in over 825 pharmaceutical, chemical and academic laboratories worldwide. Our instruments, software and consumables for parallel synthesis enable chemists to perform multiple experiments under a variety of conditions in a fraction of the time and cost of traditional methods. Forward Looking Statements Statements included in this press release that are not historical in nature may be "forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. " within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Examples of such forward-looking statements include, without limitation, statements regarding anticipated results of our collaboration with Pfizer and statements about the ability of our products to enhance chemical development. Any such forward-looking statements involve risks and uncertainties and reflect Argonaut's judgment as of the date of this release. These and other risk factors are discussed in Argonaut's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2000 filed on April 2, 2001, as amended a·mend v. a·mend·ed, a·mend·ing, a·mends v.tr. 1. To change for the better; improve: amended the earlier proposal so as to make it more comprehensive. 2. , in its most recent quarterly report on Form 10-Q Form 10-Q See 10-Q. for the quarter ended June 30, 2001 filed on August 13, 2001, and its other filings with the Securities and Exchange Commission. Argonaut disclaims any intent or obligation to update these forward-looking statements. The Company claims the protection of the Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion